How to buy VIVUS stock - 09 March

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy VIVUS stock

Own VIVUS stock in just a few minutes.


Fact checked

VIVUS, Inc is a biotechnology business based in the US. VIVUS shares (VVUS) are listed on the NASDAQ and all prices are listed in US Dollars. VIVUS employs 59 staff and has a trailing 12-month revenue of around USD$73.2 million.

How to buy shares in VIVUS

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for VIVUS. Find the stock by name or ticker symbol: VVUS. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until VIVUS reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of VIVUS, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of VIVUS. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

VIVUS share price

Use our graph to track the performance of VVUS stocks over time.

VIVUS shares at a glance

Information last updated 2021-01-13.
52-week rangeUSD$0.0697 - USD$1.88
50-day moving average USD$0.122
200-day moving average USD$0.299
Wall St. target priceUSD$1.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.596

Buy VIVUS shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stocks, Options, ETFs
Get two free stock valued between $2.50 and $250
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy VIVUS stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is VIVUS under- or over-valued?

Valuing VIVUS stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of VIVUS's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.


VIVUS's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$5.8 million.

The EBITDA is a measure of a VIVUS's overall financial performance and is widely used to measure a its profitability.

VIVUS financials

Revenue TTM USD$73.2 million
Gross profit TTM USD$43.8 million
Return on assets TTM -2.2%
Return on equity TTM 0%
Profit margin -39.28%
Book value $-4.93
Market capitalisation USD$8.3 million

TTM: trailing 12 months

Shorting VIVUS shares

There are currently 3.0 million VIVUS shares held short by investors – that's known as VIVUS's "short interest". This figure is 488.8% up from 510,645 last month.

There are a few different ways that this level of interest in shorting VIVUS shares can be evaluated.

VIVUS's "short interest ratio" (SIR)

VIVUS's "short interest ratio" (SIR) is the quantity of VIVUS shares currently shorted divided by the average quantity of VIVUS shares traded daily (recently around 871468.69565217). VIVUS's SIR currently stands at 3.45. In other words for every 100,000 VIVUS shares traded daily on the market, roughly 3450 shares are currently held short.

However VIVUS's short interest can also be evaluated against the total number of VIVUS shares, or, against the total number of tradable VIVUS shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VIVUS's short interest could be expressed as 0.17% of the outstanding shares (for every 100,000 VIVUS shares in existence, roughly 170 shares are currently held short) or 0.1704% of the tradable shares (for every 100,000 tradable VIVUS shares, roughly 170 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VIVUS.

Find out more about how you can short VIVUS stock.

VIVUS share dividends

We're not expecting VIVUS to pay a dividend over the next 12 months.

Have VIVUS's shares ever split?

VIVUS's shares were split on a 1:10 basis on 11 September 2018. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VIVUS shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for VIVUS shares which in turn could have impacted VIVUS's share price.

VIVUS share price volatility

Over the last 12 months, VIVUS's shares have ranged in value from as little as $0.0697 up to $1.88. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VIVUS's is -0.8493. This would suggest that VIVUS's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, VIVUS has bucked the trend.

VIVUS overview

VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, nonalcoholic steatohepatitis, and bariatric surgery; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; and Alvogen Malta Operations (ROW) Ltd. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California. On July 7, 2020, VIVUS, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site